Research Analysts’ Recent Ratings Updates for PROCEPT BioRobotics (PRCT)

PROCEPT BioRobotics (NASDAQ: PRCT) has recently received a number of price target changes and ratings updates:

• 8/5/2026 – PROCEPT BioRobotics had its price target lowered by TD Cowen from $34.00 to $28.00. They now have a “buy” rating on the stock.
• 8/5/2026 – PROCEPT BioRobotics was given a new $21.00 price target by Truist Financial Corporation.
• 8/5/2026 – PROCEPT BioRobotics was given a new $23.00 price target by Evercore Inc.
• 8/5/2026 – PROCEPT BioRobotics was given a new $20.00 price target by Robert W. Baird.
• 8/5/2026 – PROCEPT BioRobotics had its price target lowered by Piper Sandler from $35.00 to $25.00. They now have an “overweight” rating on the stock.
• 8/5/2026 – PROCEPT BioRobotics had its “hold” rating reaffirmed by Jefferies Financial Group Inc.. They now have a $20.00 price target on the stock.
• 8/5/2026 – PROCEPT BioRobotics was downgraded by William Blair from “outperform” to “market perform”.
• 8/5/2026 – PROCEPT BioRobotics was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $19.00 price target on the stock.
• 7/28/2026 – PROCEPT BioRobotics was downgraded by UBS Group AG from “buy” to “neutral”. They now have a $20.00 price target on the stock.
• 7/17/2026 – PROCEPT BioRobotics had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/2/2026 – PROCEPT BioRobotics had its “hold” rating reaffirmed by Truist Financial Corporation. They now have a $25.00 price target on the stock, down from $30.00.
• 7/2/2026 – PROCEPT BioRobotics was downgraded by Citigroup Inc. to “hold”.

Insider Activity at PROCEPT BioRobotics

In other PROCEPT BioRobotics news, CEO Larry L. Wood purchased 23,900 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was bought at an average cost of $20.85 per share, for a total transaction of $498,315.00. Following the completion of the transaction, the chief executive officer owned 23,900 shares in the company, valued at approximately $498,315. This represents a ? increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders have sold 1,000 shares of company stock worth $28,480 over the last quarter. 4.00% of the stock is currently owned by company insiders.

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.